Monthly Archives: April 2025

The equity markets have collapsed in 2025, the IPO window is closed, the FDA is in turmoil, the NIH is being gutted… and it’s a great time to start new biotech companies. Why?  Because there are so few being created

By Jason Campagna, CMO of Q32 Bio, as part of the From The Trenches feature of LifeSciVC We’re entering a phase shift in biotech—one that extends beyond molecules, pipelines, or even platforms. Tariff escalations, supply chain fractures, and a reassertion